aggressive tumor growth in various cancers [12] and to increase the invasive behavior of cutaneous melanoma cells [13] .
This study was designed to compare OPN and MIA plasma levels in patients with uveal melanoma both with and without metastatic disease, and to evaluate the impact of tumor size on plasma levels of both proteins.
Materials and Methods
Thirty-three plasma samples of 32 patients with uveal melanoma were analyzed. OPN and MIA plasma levels were quantified by an enzyme-linked immunosorbent assay (ELISA). Fourteen of these patients had clinically proven metastases. In 1 of the 14 patients with metastatic disease two samples were available, one taken before and one after the development of clinically detectable metastases. Screening for metastatic disease was done by a tumor specialist by using liver ultrasound and liver enzymes (alkaline phosphates, AST, ALT and bilirubin) as well as chest Xray. Abnormal findings triggered the administration of a subsequent diagnostic test such as computed tomography (CT) scan, magnetic resonance imaging (MRI) or biopsy.
Sample collection was performed after written informed consent had been obtained. The study followed the principles expressed in the Declaration of Helsinki and had been approved by the local ethics committee. Data of these 32 patients were already partly used in previous studies [10] .
Tumor height was measured by standardized echography using A-scan techniques described previously [14] at the time when blood samples were obtained from the patients. According to the tumor height measured, patients without clinically detectable metastases were divided into the following three groups: small melanomas ( 6 3 mm), medium-sized melanomas (3-5 mm) and large melanomas ( 6 5 mm).
Plasma levels of OPN and MIA were both evaluated with an ELISA test kit (R&D Systems, Minneapolis, Minn., USA and Roche, Mannheim, Germany, respectively) according to the manufacturer's instructions. The reliability and reproducibility of both kits have previously been described in the literature [9, 15] . The blood samples for the examinations of both markers were drawn from the same patients. Statistical analysis was performed using the Mann-Whitney U test, Wilcoxon test and Kruskal-Wallis test. Data were collected and analyzed using Microsoft Excel and SPSS 11.0 for Windows.
Results
Seventeen (53%) of the 32 patients were female and 15 (47%) patients were male. Patients' age varied from 37 to 81 years (median 58 years). Patients without clinically detectable metastases had a median apical tumor height of 5.0 mm. Six patients had small melanomas ( ^ 3 mm), 4 patients had medium-sized melanomas (3-5 mm) and 8 patients had large melanomas ( 6 5 mm) ( table 1 ). The median apical tumor height in patients with clinically detectable metastases was 6.5 mm.
Concerning therapy for the primary tumor in the group of patients without metastases, 15 of 18 patients had already been treated: 7 by 106 Ru plaque brachytherapy, 7 by irradiation using the gamma knife and 1 patient by enucleation. In the group of patients with metastatic disease, 12 of 14 patients had been treated for primary tumor: 5 were irradiated with the gamma knife and 1 with proton beam, 3 were treated with 106 Ru plaque brachytherapy, 2 patients received transpupillary thermotherapy (1 of them was later on enucleated because of tumor recurrence) and another patient was primarily enucleated.
The median plasma concentration of OPN in patients without clinically detectable metastases was 47.39 ng/ml (25th percentile: 37.69 ng/ml; 75th percentile: 75.49 ng/ ml) ( table 2 ). There was no statistically significant difference between plasma levels in patients with small, medium-sized or large melanoma in this study population (p 1 0.2, Kruskal-Wallis test) ( table 1 ). The median OPN level in patients with metastatic uveal melanoma was 152.01 ng/ml (25th percentile: 87.52 ng/ml; 75th percentile: 233.45 ng/ml). The difference between patients with and without clinically detectable metastases was statistically highly significant (p ! 0.001, Mann-Whitney U test) ( fig. 1 , table 2 ) .
The median MIA level in patients without metastatic disease was 5.64 ng/ml (25th percentile: 4.63 ng/ml; 75th percentile: 8.0 ng/ml) ( table 2 ). As for OPN, no correlation could be found between MIA level and tumor height in this group (p 1 0.7, Kruskal-Wallis test) ( table 1 ). The median MIA level for patients with metastatic disease was 13.11 ng/ml (25th percentile: 8.89 ng/ml; 75th percentile: 37.05 ng/ml). As for OPN, the difference between the MIA levels in patients with and without clinically detectable metastases was statistically significant (p ! 0.001, Mann-Whitney U test) ( fig. 1 b, table 2 ).
In the patient with metastatic disease, in whom the levels of OPN and MIA could be measured before and after the development of metastases, the concentrations of OPN and MIA were 118.67 and 9.8 ng/ml before and 375.54 and 26.53 ng/ml after generalization, respectively (p ! 0.001, Wilcoxon test).
In general, a comparison between OPN or MIA plasma levels and tumor burden or stage of metastases was very difficult, because all 14 patients had diffuse liver metastases. The median time gap between diagnosis of metastases and sample collection was 3 months.
Discussion
There are several established parameters to identify patients at high risk of metastatic disease such as histological cell type, largest tumor diameter, tumor location and specific microcirculation patterns [2, 16] . All these predictors of metastatic disease may help to indicate the risk of developing metastatic disease; they are, however, not able to detect metastatic disease itself.
The protein MIA, an attachment regulating protein, was already described as a tumor marker for cutaneous melanomas [15] . MIA specifically inhibits the attachment of melanoma cells to fibronectin and laminin and is therefore presumed to influence the detachment of melanoma cells from extracellular matrix. Therefore, MIA is considered to play an important role in the pathogenesis of metastases.
As in earlier studies [6] [7] [8] we were again able to demonstrate that elevated MIA plasma levels indicate metastatic disease also in the malignant melanoma of the uvea. These results have recently been confirmed by Barak et al. [17] .
OPN is a 314-amino acid phosphoglycoprotein that is a component of the noncollagenous bone matrix. OPN has been described in the context of diverse physiological roles such as chemotaxis, cell migration and adhesion, angiogenesis, apoptosis, cell-extracellular matrix interactions and immune regulation [18] . OPN actively promotes the tumorigenic phenotype and contributes to metastases. Increased OPN expression is associated with aggressive behavior and metastases in breast, colon, prostate, lung, liver and ovarian cancers [11] . OPN is secreted into the blood where it can be detected by ELISA. Elevated plasma levels have been observed in patients with advanced or metastatic cancers, including cutaneous mela- noma [12, 13] . Increased OPN plasma levels have recently also been described in patients with metastatic uveal melanoma [9, 10, 17] .
The present study was undertaken to compare plasma levels of MIA and OPN in patients with and without metastases from uveal melanoma and to assess a possible correlation between tumor height and MIA or OPN plasma levels in patients without clinically detectable metastases.
We found a significant difference between plasma levels in patients with and without clinically detectable metastases for both markers. As 1 patient in our study group developed metastases during the observation period, we were able to observe a marked increase for both MIA and OPN plasma levels along with the generalization of the tumor. This indicates that, in addition to the registration of single values of OPN or MIA plasma levels, the development or deviation from individual baseline values of these plasma levels over time should be taken into account [6, 7, 19] .
In the group of patients without clinically detectable metastases there was no statistically significant difference between the plasma levels both of MIA and OPN in patients with small, medium-sized or large melanomas. This confirms our previous results [6] [7] [8] and suggests that both markers are independent of tumor size. In all three groups the plasma levels of both markers were statistically similar to those in healthy control groups [15] . As described for other tumor markers in medicine, these results suggest that OPN and MIA are not adequate to diagnose or stage a primary tumor.
In order to evaluate the quality of a diagnostic test a receiver-operating-characteristic curve (ROC) would be of great value. In this analysis, the true-positive rate (sensitivity) is plotted against the false-positive rate (100 -specificity) for different cutoff points. A test with perfect discrimination has an ROC plot that passes through the upper left corner (100% sensitivity, 100% specificity). Therefore the closer the ROC plot is to the upper left corner, the higher the overall accuracy of the test. Another parameter for the quality of a diagnostic test in this analysis is the area under the curve [20] .
Recently, ROC curves were published for OPN and MIA [17] . Such an analysis must, however, be based on a larger amount of data: a minimum of 50 patients in each group should be included for a statistically relevant calculation [20] . We hope to give a valid calculation after inclusion of a larger number of patients into the current investigation.
In summary, OPN as well as MIA represent useful and cheap markers for the detection of metastatic disease and for the monitoring of patients with primary uveal melanoma. A low sensitivity of liver function testing (60% for alkaline phosphates, 50% for AST and 40% for ALT) [17] as well as of abdominal ultrasonography and chest radiography [5] has already been demonstrated in the literature. Barak et al. [17] were able to demonstrate a considerably higher sensitivity and specificity of MIA and OPN, and that the combination of these two biomarkers was far superior to liver function testing. Therefore, it may be hypothesized that MIA and OPN could represent valuable tools even for the early detection of metastasis in these patients, if applied routinely.
The combination of both markers might increase the reliability of early detection giving our patients a chance for early intervention and prolonged survival. In the clinical practice, OPN and MIA plasma levels could be measured for instance 3-4 times per year instead of liver function testing. In case of abnormal levels, subsequent tests such as CT scan, MRI or biopsy could be performed.
In addition, MIA and OPN could play an important role in the monitoring of new treatment options for metastatic uveal melanoma.
